Acetyl Salicylic Acid in Elderly Patientsgerman translation / full article
Can secondary prevention by acetyl salicylic acid (ASA) treatment of coronary artery disease (CAD) and cerebral ischemia reduce cardiovascular risk?
A subgroup analysis of a large (but possibly flawed) randomised controlled study showed a signficant risk reduction in patients over 75 years treated by ASA as secondary prevention of cerebral ischemia. A specific analysis for CAD, however, was not done. There is insufficient evidence to draw final conclusions about efficacy of ASA in secondary prevention in elderly patients.